Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GenSight Biologics S A : Amendment to the 2019 Universal Registration Document

10/22/2020 | 12:40pm EST

AMENDMENT

TO THE 2019 UNIVERSAL REGISTRATION

DOCUMENT

GenSight Biologics S.A.

A limited liability company with a board of directors (société anonyme à conseil d'administration) incorporated and organized under the laws of France with a share capital of €843,459.05

Registered Office:

74, rue du Faubourg Saint-Antoine

75012 Paris, France

751 164 757 Paris Trade and Companies Register

AMENDMENT

TO THE 2019 UNIVERSAL REGISTRATION

DOCUMENT

This amendment to the 2019 Universal Registration Document was filed on October 22, 2020 with the AMF (the French Financial Markets Regulator), as the competent authority under Regulation (EU) 2017/1129, without prior approval in accordance with Article 9 of the said Regulation.

This Universal Registration Document may be used for the purpose of a public offer of securities or the admission of securities to trading on a regulated market if it supplemented by a securities note and, as the case may be, by a summary and all the amendments to the Universal Registration Document. These documents are together approved by the AMF in accordance with Regulation (EU) 2017/1129.

Pursuant to article 19 of Regulation (EU) 2017/1129, this amendment updates the universal registration document filed with the AMF on April 8, 2020 under number D.20-0271 (the "2019 Universal Registration Document") and updates the necessary information pursuant to the regulation (the "Amendment")

A concordance table is provided in this Amendment in order to facilitate the retrieval of the information incorporated by reference and that which are updated or amended.

Copies of this Amendment and of the 2019 Universal Registration Document are available free of charge from GenSight (74, rue du Faubourg Saint-Antoine 75012 Paris, France) and on its website (https://www.gensight-biologics.com).

These documents are also available in an electronic format on the AMF's website (https://www.amf-france.org/).

CONCORDANCE TABLE

The concordance table below identifies the information required by the annex 1 and 2 of the delegated Regulation of March 14, 2019 in accordance with the Universal Registration Document template as well as their correspondence with the sections of our 2019 Universal Registration Document.

Section(s) of the 2019

Section(s) of the

Universal Registration

Amendment

Document

1. PERSON RESPONSIBLE, THIRD PARTY INFORMATION, EXPERT'S

REPORTS AND COMPETENT AUTHORITY APPROVAL

1.1 Identity of the person responsible

1.1

1.2 Declaration of the person responsible

1.2

1.2

1.3 Expert's report

1.3

1.4 Third party information

1.4

1.5 Competent authority approval

1.5

2. STATUTORY AUDITORS

2.1 statutory auditors

2.1

2.2 change in statutory auditors

2.2

3. RISK FACTORS

3.1 Description of the main significant risks

3.1 to 3.7

2.1 to 2.4

4. INFORMATION ABOUT THE ISSUER

4.1 Legal and commercial name

4.1

4.2 Place of registration, registration number and legal entity identifier ("LEI")

4.2

4.3 Date of incorporation, length of life of the issuer

4.3

4.4 Domicile, legal form, legislation, country of incorporation, address,

4.4

telephone number and website

5. BUSINESS OVERVIEW

5.1 Business overview

5.1

3.1

5.1.1 Nature of the business and main activities

5.1

3.3 to 3.4

5.2 Our product development pipeline

5.2

3.2

5.3 Important events in the development of the Company

5.3

3.5

5.4 Strategy and Objectives

5.4

5.5 Research and Development, patents and licenses

5.5

5.6 Competition

5.6

5.7 Investments

5.7

5.7.1 Important realized Investissement

5.7.1

5.7.2 Important on-going or engaged Investissement

5.7.2

5.7.3 Joint ventures and significant interests

5.7.3

5.7.4 Environment impact from the use of tangible assets

5.7.4

6. ORGANIZATIONAL STRUCTURE

6.1 Overview of the organizational structure

6

6.2 Important subsidiaries

6

7. OPERATING AND FINANCIAL REVIEW

7.1 Financial situation

7.1

4

7.1.1 Financial operations overview

7.2

7.1.2 Future evolution and Research and Development activities

7.2.4.1

7.2 Results of operations

7.3

4

7.2.1 Important factors

N/A

7.2.2 Major changes in net sales or revenues

7.3

2 - GENSIGHT BIOLOGICS - Amendment to the 2019 Universal Registration Document

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Gensight Biologics SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 16:39:02 UTC


© Publicnow 2020
All news about GENSIGHT BIOLOGICS S.A.
11/04GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
11/03GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
11/03GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately €25 millio..
PU
More news
Financials
Sales 2020 12,5 M 15,1 M 15,1 M
Net income 2020 -16,7 M -20,2 M -20,2 M
Net cash 2020 16,7 M 20,2 M 20,2 M
P/E ratio 2020 -11,5x
Yield 2020 -
Capitalization 271 M 327 M 328 M
EV / Sales 2020 20,4x
EV / Sales 2021 17,7x
Nbr of Employees 25
Free-Float 95,4%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 6,84 €
Spread / Highest target 105%
Spread / Average Target 49,6%
Spread / Lowest Target -2,05%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.175.25%349
GILEAD SCIENCES, INC.-5.92%76 616
VERTEX PHARMACEUTICALS3.54%59 887
REGENERON PHARMACEUTICALS34.64%54 257
WUXI APPTEC CO., LTD.64.21%39 976
BIONTECH SE257.41%27 452